

Former US Ambassador and Assistant Director-General of the World Health Organization on HIV/AIDS, Tuberculosis and Malaria Dr. Jack C. Chow Joins Draganfly Board of Advisors

Dr. Chow to work with Draganfly to implement the Vital Intelligence camera and drone technology in the United States to combat COVID-19 (Coronavirus)

Vancouver, British Columbia – April 8, 2020 (**GLOBE NEWSWIRE**) - Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) ("**Draganfly**" or the "**Company**"), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle ("**UAV**"), Remotely Piloted Aircraft Systems ("**RPAS**"), and unmanned vehicle sector ("**UVS**"), today announced that its Board of Directors has appointed Dr. Jack C. Chow as an advisory member to its Board.

Draganfly announced on March 26, 2020 that it had been selected as the exclusive global systems integrator for the Vital Intelligence Project a healthcare data services & deep learning company in conjunction with the University of South Australia, using technology developed with help from the Australian Department of Defence Science and Technology Group. The Vital Intelligence Project is a health and respiratory monitoring platform utilizing new and existing camera networks as well as UAVs and RPAS being immediately commercialized for health monitoring and detection of infectious and respiratory conditions.

Dr. Chow held the rank of ambassador as the Special Representative on Global HIV/AIDS for Secretary of State Colin Powell and as the Deputy Assistant Secretary of State for Health and Science, the first U.S. diplomat of ambassador rank appointed to a public health mission. He led American diplomatic efforts in the establishment of the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and in countering global infectious diseases and bioterrorism threats.

In previous positions, Dr. Chow served as a senior official at the State Department's global affairs office, both the House and Senate Appropriations Committees, the Public Health Service at HHS, the Fogarty International Center of NIH, and the White House Office of Science and Technology Policy. In the private sector, he has been a consultant on global health at the RAND Corporation, McKinsey & Company, and PRTM/PwC.

He is currently Distinguished Professor on Global Health at Carnegie Mellon University, Heinz College for Public Policy. He has served multiple times as a Sharkey Distinguished Visiting Scholar at Seton Hall University's School of Diplomacy and International Affairs. He was a 2013 Fellow at the Harvard Advanced Leadership Initiative, where he conducted research on the structure and design of national strategic policies.

"We are incredibly honoured to have Jack join our board of advisors. His experience working with the World Health Organization and his efforts on countering global infectious diseases and bioterrorism threats is incredibly insightful for the Vital Intelligence project that Draganfly has been selected to work on," said Cameron Chell, Draganfly CEO.

"I extremely honoured to have been asked to join Draganfly's board of advisors," said Dr. Chow. "Working with this extraordinary team which will commercialize a platform for health monitoring and detection of infectious and respiratory conditions is very important as we enter a new world in health services."

Dr. Chow earned an MS in Health Policy from the University of California, Berkeley, his MD from the University of California, San Francisco, an MPA in International Policy from Harvard, and an MBA in Finance from the Chicago Booth School of Business.

Draganfly Board of Directors appointed Former White House Chief of Staff and US Secretary of Transportation Andrew H. Card as Director of the company in November 2019, Julie Myers Wood, Presidential Appointee and Former Assistant Secretary of Homeland Security to the Draganfly board of advisors on March 3, 2020 and Molly Wilkinson, American Airlines VP of Regulatory Affairs and former Republican General Counsel for Homeland Security.

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge, UVS and software that revolutionizes the way people do business. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer within the commercial UAV and UVS space, serving the public safety, agriculture, industrial inspections and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money and lives.

For more information on Draganfly, please visit us at www.draganfly.com.

For additional investor information, visit <https://www.thecse.com/en/listings/technology/draganfly-inc>, <https://www.otcmarkets.com/stock/DFLYF/overview> or <https://www.boerse-frankfurt.de/aktie/draganfly-inc>.

Media Contact

Arian Hopkins

email: media@draganfly.com

Company Contact Phone: 1-306-955-9907

Email: info@draganfly.com

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.